Research Article | | Peer-Reviewed

Anthropometric and Biochemical Findings in Non-Alcoholic Fatty Liver Disease with or Without Diabetes

Received: 1 October 2023    Accepted: 30 October 2023    Published: 22 December 2023
Views:       Downloads:
Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) has emerged as a prevalent cause of chronic liver diseases globally in the past decade, posing significant risks to liver health, cardiovascular well-being, and even warranting consideration for liver transplantation. There is limited research on the clinical, anthropometric, biochemical, and metabolic characteristics of NAFLD patients, both with and without diabetes, in Bangladesh. Aim of the study: This study aimed to assess the prevalence of diabetes and non-diabetes among a group of NAFLD patients and to investigate the anthropometric, biochemical, and metabolic profiles of NAFLD patients with diabetes compared to those without diabetes. Methods: This prospective observational study was conducted at the Department of Gastrointestinal Hepatobiliary & Pancreatic Disorder (GHPD), BIRDEM General Hospital, Dhaka, from April 2014 to April 2015. A total of 111 individuals with ultrasonographically diagnosed NAFLD were included in the study. Participants underwent assessments for various parameters, including anthropometric measurements, biochemical assays (including blood glucose levels, liver function tests, lipid profiles, and HOMA-IR), and the presence of diabetes or metabolic syndrome (as defined by IDF criteria). The patients were categorized and analyzed based on the presence or absence of diabetes. Statistical analysis was performed using SPSS version 16.0. Results: Among the 111 NAFLD patients, 71 (63.96%) were diagnosed with diabetes, while 40 (36.04%) did not have diabetes. In comparison to those without diabetes, NAFLD patients with diabetes tended to be older (47.15±10.26 vs. 43.35±10.7 years) and included a higher proportion of females (61.98% vs. 57.50%). They also had a significantly higher prevalence of hypertension (77.47% vs. 40.0%; p<0.001), dyslipidemia (64.79% vs. 40.0%; p=0.01), and metabolic syndrome (74.64% vs. 30.0%; p<0.001). Diabetic NAFLD patients had a higher mean body mass index (BMI) compared to non-diabetic NAFLD patients (27.09±3.98 vs. 25.18±3.58 kg/m2; p=0.01). Most patients, both with diabetes (87.32%) and without diabetes (80%), had central obesity. Additionally, diabetic NAFLD patients exhibited higher waist circumference, hip circumference, waist-to-hip ratio, waist-to-height ratio, systolic blood pressure, and diastolic blood pressure when compared to non-diabetic NAFLD patients. Serum levels of ALT, AST, GGT, and ALP were significantly elevated in the diabetic group. While triglyceride levels, total cholesterol, LDL-cholesterol, and fasting insulin levels were also higher in diabetic NAFLD patients, these differences were not statistically significant. However, insulin resistance, as measured by HOMA-IR, was significantly higher in diabetic NAFLD patients. Conclusion: NAFLD patients with diabetes exhibit greater metabolic risk factors, including higher BMI, central obesity, hypertension, elevated triglyceride levels, and increased insulin resistance, all of which may contribute to the progression of non-alcoholic steatohepatitis (NASH) and advanced fibrosis. Notably, a substantial proportion of NAFLD patients without diabetes also display metabolic risk factors, highlighting the importance of recognizing NAFLD in individuals without diabetes.

Published in International Journal of Gastroenterology (Volume 7, Issue 2)
DOI 10.11648/j.ijg.20230702.16
Page(s) 77-86
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Non-Alcoholic Fatty Liver Disease (NAFLD), Chronic Liver Diseases

References
[1] Neuschwander-Tetri BA and Caldwell SH, 2003. Nonalcoholic Steatohepatitis: Summary of an ASLD Single Topic Conference. Hepatology 37: 1202-1219.
[2] Angulo P. 2002. Nonalcoholic Fatty Liver Disease. N Engl J Med 346: 1221-1231.
[3] Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002; 2:2. doi: 10.1186/1471-230x-2-2. Epub 2002 Jan 22. PMID: 11835693; PMCID: PMC65516.
[4] Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 May; 158 (7): 1851-1864. doi: 10.1053/j.gastro.2020.01.052. Epub 2020 Feb 13. PMID: 32061595.
[5] Singh, S. P., Nayak, S., Swain, M., Rout, N., Mallick, R. N., Agarwal, O., Meher, C. and Rao, M. 2004. Prevalence of Nonalcoholic Fatty Liver Disease in Coastal Eastern India: A Preliminary Ultrasonographic Survey. Tropical Gastroenterology. 25 (2): 76-9.
[6] Fan JG, Zhu J, Li XJ et al. 2005. Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol. 20: 1825-32.
[7] Fan JG, Saibara T, Chitturi S, Sung JJY, Kim BI, Chutaputti A, 2007. The Asia–Pacific working party for NAFLD. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia–Pacific? J. Gastroenterol. Hepatol. 22: 794-800.
[8] Younossi ZM, Stepanovo M, Fang Y, Younossi Y, Mir H, Shrishard M. 2011. Changes in prevalence of the most common causes of chronic liver disease in United States from 1988 to 2008. Clin Gastroenterol Hepatol. 9 (6): 524-30.
[9] Sanyal AJ. 2002. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology; 123: 1705-25.
[10] Fassio, E, Alvarez, E, Dominguez, N, Landeira, G. and Longo, C, 2004. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40: 820-826.
[11] Angulo P, Lindor KD, 2002. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17 (Supp-1): S186-S190.
[12] Grattagliano I, Portincasa P, Palmieri VO, Palasciano G, 2007. Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can Fam Physician, 53: 8.
[13] Z. M. Younossi, M. J. Reyes, A. Mishra, R. Mehta, L. Henry. 2014. Systematic review with meta-analysis: non-alcoholic steatohepatitis- a case for personalised treatment based on pathogenic targets Aliment. Pharmacol. Ther. 39 (1): 3-14.
[14] Hui JM, Hodge A, Farell GC, Kench JG, Kriketos A, George J, 2004. Beyond Insulin resistance in NASH; TNF alpha or adiponectin. Hepatology. 40: 46-54.
[15] E. Bugianesi, A. J. McCullough, G. Marchesini, 2005. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 42 (5), pp. 987–1000.
[16] Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. 2003. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 37: 917-923.
[17] Chitturi S, Farrell GC, 2001. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 21: 27-41.
[18] Chitturi S, Farrell G, Frost L, et al. 2002. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 36 (2): 403-409.
[19] Wild S, Roglic G, Green A, Sicree R, King H. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care; 27, 1047-53.
[20] Stone BG, Van Thiel DH. 1985. Diabetes mellitus and the liver. Semin Liv Dis. 5: 828.
[21] Foster KJ, Griffith AH, Dewbury K, et al. 1980. Liver disease in patients with diabetes mellitus. Postgrad Med J. 56: 767–772.
[22] Silverman JF, Pories WJ, Caro JF. 1989. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu. 24: 275-302.
[23] H. B. El-Serag, T. Tran, J. E, 2004. Everhart. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology, 126 (2) pp. 460–468.
[24] Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, et al. 2009. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 7 (11): 1224-9.
[25] Neuschwander-Tetri, B. A, Clark, J. M, Bass, N. M, Van Natta, M. L, Unalp-Arida, A, Tonascia, J. et al. 2010. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52: 913-924.
[26] Tolman KG, Fonseca V, Tan MH, Dalpiaz A. 2004. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 21; 141: 946-56.
[27] Roberto De Marco, Francesca Locatelli, Giacomo Zoppini, Giuseppe Verlato, Enzo Bonora, Michele Muggeo. 1999. Cause -Specific Mortality in Type 2 Diabetes- The Verona Diabetes Study. Diabetes Care. 22: 756-61.
[28] Das, S, Singh, S. P, Parida, P. K. and Mallick, R. N, 2010. Non-Alcoholic Fatty Liver Disease in Subjects with Type 2 Diabetes Mellitus and Non-Diabetics with Special Reference to Insulin Resistance and Hepatic Histopathological Changes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 4, 226-229.
[29] Loria P, Lonardo A, Carulli L, Verrone AM, Ricchi M, Lombardini S, et al. 2005. Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 22 (Suppl-2): 31-6.
[30] Targher G, Arcaro G. 2007. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 191 (2): 235-40.
[31] Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Man CD, et al. 2006. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Nat Acad Sci. 103: 18273-27.
[32] Succurro E, Marini MA, Frontoni S, Hribal ML, Andreozzi F, Lauro R, et al. 2008. Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity (Silver Spring). 16: 1881-6.
[33] Fabbrini E, Sullivan S, Klein S, 2010. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatol. 51: 679-89.
[34] Osterreicher C. H. and D. A. Brenner, 2007. The genetics of nonalcoholic fatty liver disease. Ann Hepatol. 6 (2): 83-8.
[35] Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 40 (12): 1461-5.
[36] Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ, Jun 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 55 (6): 2005-23.
[37] Browning, J. D, Szczepaniak, L. S, Dobbins, R, Nuremberg, P, Horton, J. D, Cohen, J. C. et al. 2004b. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395.
[38] Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H, 2007. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92: 3490–3497.
[39] Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A, Schick F, Haring H, Stumvoll M 2005. Elevated serum GGT concentrations predict reduced insulin sensitivity and increase intrahepatic lipids. Horm Metab Res 37: 246-251.
[40] Di Lelio A, Cestari C, Lomazzi A, Beretta L, 1989. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology. 172 (2): 389–92.
[41] Dowman, J. K, Tomlinson, J. W. and Newsome, P. N. 2011. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 33: 525-540.
[42] Wong, V. W., Vergniol, J., Wong, G. L., Foucher, J., Chan, H. L., Le Bail, B. et al. 2010. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51: 454-462.
[43] Shivaram Prasad Singh, Ayaskanta Singh, Girish Kumar Pati, Bijay Misra, Debasis Misra, Sanjib Kumar Kar, et al. 2014. A Study of Prevalence of Diabetes and Prediabetes in Patients of Non-Alcoholic Fatty Liver Disease and the Impact of Diabetes on Liver Histology in Coastal Eastern India. Journal of Diabetes Mellitus. 4, 290-296.
[44] Shahinul Alam & Utpal Das Gupta & Mahbubul Alam & Jahangir Kabir & Ziaur Rahman Chowdhury & A. K. M. Khorshed Alam. 2014. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian Society of Gastroenterology. 33 (5): 452-7.
[45] Shahinul Alam, Sheikh Mohammad Noor-E-Alam, Ziaur Rahman Chowdhury, Mahabubul Alam, Jahangir Kabir. 2013. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol. 5 (5): 281-287.
[46] Sheth SG, Gordon FD, Chopra S. 1997. Nonalcoholic steatohepatitis. Ann Intern Med 126 (2): 137-145.
[47] Li H, Wang YJ, Tan K, Zeng L, Liu L, Liu FJ, Zhou TY, Chen EQ, Tang H, 2009. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary Pancreat Dis Int; 8: 377-382.
[48] Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. 2006. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 21: 138-143.
[49] Mohan V, Farooq S, Deepa, M, et al. 2009. Prevalence of Nonalcoholic Fatty Liver Disease in Urban South Indians in Relations to Different Grades of Glucose Intolerance and Metabolic Syndrome. Diabetes Research and Clinical Practice, 84: 84-91.
[50] Clark JM, Brancati FL, Diehl AM, 2003. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol; 98: 960-967.
[51] Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. 2009. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 57: 205-10.
[52] Banerjee S, Ghosh US, Dutta S, 2008. Clinic pathological profile of hepatic involvement in type-2 diabetes mellitus and its significance. J Assoc Physicians India. 56: 593-9.
[53] Adams LA, Lymp J. F, St Sauver J, Sanderson S, Lindor, K. D, Feldstein A. et al. 2005a. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 129: 113-121.
[54] Juanwen, Zhang, Zhao Ying, Xu Chengfu, Hong Yani, Lu Huanle, Wu Jianping, et al. 2014. "Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study." Scientific reports 4: 5832. doi: 10.1038/srep05832.
[55] Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, Fukui M, Nagata C, Takeda J, 2012. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 18 (13): 1508–1516.
[56] Manco M, Bedogni G, Marcellini M, Devito R, Ciampalini P, Sartorelli MR, Comparcola D, Piemonte F, Nobili V, 2008. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut; 57: 1283-1287.
[57] Ekstedt, M, Franzen, L. E, Mathiesen, U. L, Thorelius, L, Holmqvist, M, Bodemar, G. et al. 2006. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873.
[58] Marchesini G, Brizi M, Bianchi G, et al. 2001. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 50: 1844-50.
[59] Kim HJ, Kim HJ, Lee KE, et al. 2004. Metabolic significance of nonalco- holic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 164: 2169-75.
[60] Edmison J, McCullough AJ, 2007. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis. 11: 75-104.
Cite This Article
  • APA Style

    Mawla Ali Sheikh, M., Anisur Rahman, M., Mahmud Bhuiyan, T., Golam Azam, M. (2023). Anthropometric and Biochemical Findings in Non-Alcoholic Fatty Liver Disease with or Without Diabetes. International Journal of Gastroenterology, 7(2), 77-86. https://doi.org/10.11648/j.ijg.20230702.16

    Copy | Download

    ACS Style

    Mawla Ali Sheikh, M.; Anisur Rahman, M.; Mahmud Bhuiyan, T.; Golam Azam, M. Anthropometric and Biochemical Findings in Non-Alcoholic Fatty Liver Disease with or Without Diabetes. Int. J. Gastroenterol. 2023, 7(2), 77-86. doi: 10.11648/j.ijg.20230702.16

    Copy | Download

    AMA Style

    Mawla Ali Sheikh M, Anisur Rahman M, Mahmud Bhuiyan T, Golam Azam M. Anthropometric and Biochemical Findings in Non-Alcoholic Fatty Liver Disease with or Without Diabetes. Int J Gastroenterol. 2023;7(2):77-86. doi: 10.11648/j.ijg.20230702.16

    Copy | Download

  • @article{10.11648/j.ijg.20230702.16,
      author = {Md. Mawla Ali Sheikh and Md. Anisur Rahman and Tareq Mahmud Bhuiyan and Md. Golam Azam},
      title = {Anthropometric and Biochemical Findings in Non-Alcoholic Fatty Liver Disease with or Without Diabetes},
      journal = {International Journal of Gastroenterology},
      volume = {7},
      number = {2},
      pages = {77-86},
      doi = {10.11648/j.ijg.20230702.16},
      url = {https://doi.org/10.11648/j.ijg.20230702.16},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijg.20230702.16},
      abstract = {Background: Non-alcoholic fatty liver disease (NAFLD) has emerged as a prevalent cause of chronic liver diseases globally in the past decade, posing significant risks to liver health, cardiovascular well-being, and even warranting consideration for liver transplantation. There is limited research on the clinical, anthropometric, biochemical, and metabolic characteristics of NAFLD patients, both with and without diabetes, in Bangladesh. Aim of the study: This study aimed to assess the prevalence of diabetes and non-diabetes among a group of NAFLD patients and to investigate the anthropometric, biochemical, and metabolic profiles of NAFLD patients with diabetes compared to those without diabetes. Methods: This prospective observational study was conducted at the Department of Gastrointestinal Hepatobiliary & Pancreatic Disorder (GHPD), BIRDEM General Hospital, Dhaka, from April 2014 to April 2015. A total of 111 individuals with ultrasonographically diagnosed NAFLD were included in the study. Participants underwent assessments for various parameters, including anthropometric measurements, biochemical assays (including blood glucose levels, liver function tests, lipid profiles, and HOMA-IR), and the presence of diabetes or metabolic syndrome (as defined by IDF criteria). The patients were categorized and analyzed based on the presence or absence of diabetes. Statistical analysis was performed using SPSS version 16.0. Results: Among the 111 NAFLD patients, 71 (63.96%) were diagnosed with diabetes, while 40 (36.04%) did not have diabetes. In comparison to those without diabetes, NAFLD patients with diabetes tended to be older (47.15±10.26 vs. 43.35±10.7 years) and included a higher proportion of females (61.98% vs. 57.50%). They also had a significantly higher prevalence of hypertension (77.47% vs. 40.0%; pConclusion: NAFLD patients with diabetes exhibit greater metabolic risk factors, including higher BMI, central obesity, hypertension, elevated triglyceride levels, and increased insulin resistance, all of which may contribute to the progression of non-alcoholic steatohepatitis (NASH) and advanced fibrosis. Notably, a substantial proportion of NAFLD patients without diabetes also display metabolic risk factors, highlighting the importance of recognizing NAFLD in individuals without diabetes.
    },
     year = {2023}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Anthropometric and Biochemical Findings in Non-Alcoholic Fatty Liver Disease with or Without Diabetes
    AU  - Md. Mawla Ali Sheikh
    AU  - Md. Anisur Rahman
    AU  - Tareq Mahmud Bhuiyan
    AU  - Md. Golam Azam
    Y1  - 2023/12/22
    PY  - 2023
    N1  - https://doi.org/10.11648/j.ijg.20230702.16
    DO  - 10.11648/j.ijg.20230702.16
    T2  - International Journal of Gastroenterology
    JF  - International Journal of Gastroenterology
    JO  - International Journal of Gastroenterology
    SP  - 77
    EP  - 86
    PB  - Science Publishing Group
    SN  - 2640-169X
    UR  - https://doi.org/10.11648/j.ijg.20230702.16
    AB  - Background: Non-alcoholic fatty liver disease (NAFLD) has emerged as a prevalent cause of chronic liver diseases globally in the past decade, posing significant risks to liver health, cardiovascular well-being, and even warranting consideration for liver transplantation. There is limited research on the clinical, anthropometric, biochemical, and metabolic characteristics of NAFLD patients, both with and without diabetes, in Bangladesh. Aim of the study: This study aimed to assess the prevalence of diabetes and non-diabetes among a group of NAFLD patients and to investigate the anthropometric, biochemical, and metabolic profiles of NAFLD patients with diabetes compared to those without diabetes. Methods: This prospective observational study was conducted at the Department of Gastrointestinal Hepatobiliary & Pancreatic Disorder (GHPD), BIRDEM General Hospital, Dhaka, from April 2014 to April 2015. A total of 111 individuals with ultrasonographically diagnosed NAFLD were included in the study. Participants underwent assessments for various parameters, including anthropometric measurements, biochemical assays (including blood glucose levels, liver function tests, lipid profiles, and HOMA-IR), and the presence of diabetes or metabolic syndrome (as defined by IDF criteria). The patients were categorized and analyzed based on the presence or absence of diabetes. Statistical analysis was performed using SPSS version 16.0. Results: Among the 111 NAFLD patients, 71 (63.96%) were diagnosed with diabetes, while 40 (36.04%) did not have diabetes. In comparison to those without diabetes, NAFLD patients with diabetes tended to be older (47.15±10.26 vs. 43.35±10.7 years) and included a higher proportion of females (61.98% vs. 57.50%). They also had a significantly higher prevalence of hypertension (77.47% vs. 40.0%; pConclusion: NAFLD patients with diabetes exhibit greater metabolic risk factors, including higher BMI, central obesity, hypertension, elevated triglyceride levels, and increased insulin resistance, all of which may contribute to the progression of non-alcoholic steatohepatitis (NASH) and advanced fibrosis. Notably, a substantial proportion of NAFLD patients without diabetes also display metabolic risk factors, highlighting the importance of recognizing NAFLD in individuals without diabetes.
    
    VL  - 7
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Gestro-Medicine, IBN Sina Medical College Hospital, Dhaka, Bangladesh

  • Department of Gastrointestinal Hepatobiliary & Pancreatic Disorder (GHPD), BIRDEM General Hospital, Dhaka, Bangladesh

  • Department of Gastrointestinal Hepatobiliary & Pancreatic Disorder (GHPD), BIRDEM General Hospital, Dhaka, Bangladesh

  • Department of Gastrointestinal Hepatobiliary & Pancreatic Disorder (GHPD), BIRDEM General Hospital, Dhaka, Bangladesh

  • Sections